Pembrolizumab and Chemoradiotherapy for the Treatment of Unresectable Gastroesophageal Cancer
Status:
Recruiting
Trial end date:
2022-01-18
Target enrollment:
Participant gender:
Summary
This phase I trial investigates how well pembrolizumab and chemoradiotherapy works in
treating patients with gastroesophageal cancer that cannot be removed by surgery
(unresectable). Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the
body's immune system attack the cancer, and may interfere with the ability of tumor cells to
grow and spread. Chemotherapy drugs, such as fluorouracil, oxaliplatin and docetaxel work in
different ways to stop the growth of tumor cells, either by killing the cells, by stopping
them from dividing, or by stopping them from spreading. Radiation therapy uses high energy
photons to kill tumor cells and shrink tumors. Giving pembrolizumab together with
chemoradiotherapy may help to control gastroesophageal cancer.